Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Alexandria Real Estate Equities

Founders Joel Marcus

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 53
Average round size
info
The average size of a deal this fund participated in
$20M
Portfolio companies 40
Rounds per year 1.77
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.23
Exits 14
Key employees 1
Stages of investment
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

Alexandria Real Estate Equities appeared to be the Corporate Investor, which was created in 1994. The company was established in North America in United States. The main department of described Corporate Investor is located in the Pasadena.

The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this Corporate Investor is 18 percentage points less often commits exit comparing to other organizations. The increased amount of exits for fund were in 2014. The typical startup value when the investment from Alexandria Real Estate Equities is 10-50 millions dollars. Comparing to the other companies, this Alexandria Real Estate Equities performs on 7 percentage points less the average number of lead investments. The fund is constantly included in less than 2 deals per year.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the various public portfolio startups of the fund, we may underline KSQ Therapeutics, Cydan, OncoResponse Among the most successful fund investment fields, there are Pharmaceutical, Life Science. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.

The current fund was established by Joel Marcus. Besides them, we counted 1 critical employee of this fund in our database.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Alexandria Real Estate Equities, startups are often financed by Polaris Partners, MPM Capital, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, MPM Capital, Polaris Partners. In the next rounds fund is usually obtained by ARCH Venture Partners, Polaris Partners, Amgen Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Alexandria Real Estate Equities:
Typical Co-investors
Alexandria Real Estate Equities is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Alexandria Real Estate Equities:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

TFC Therapeutics

Biopharma
Biotechnology
Medical
17 Aug 2023 Nyack, New York, United States

Stablix

Biotechnology
Health Care
Medical
$63M03 Jun 2021 New York, New York, United States

Cradle Genomics

Biotechnology
$17M16 Jul 2019 San Diego, California, United States

Strand Therapeutics

Biotechnology
Therapeutics
$6M04 Jun 2019 Cambridge, Massachusetts, United States

KSQ Therapeutics

Biopharma
Biotechnology
Pharmaceutical
Therapeutics
$80M28 Sep 2018 Cambridge, Massachusetts, United States

KSQ Therapeutics

Biopharma
Biotechnology
Pharmaceutical
Therapeutics
$76M02 Oct 2017 Cambridge, Massachusetts, United States

Arbor Biotechnologies

Biopharma
Biotechnology
Life Science
$15M01 Jun 2017 Cambridge, Massachusetts, United States

Frequency Therapeutics

Biotechnology
Genetics
Medical
$32M11 Apr 2017 Woburn, Massachusetts, United States

GenePeeks

Biotechnology
Genetics
$16M24 Jan 2017 New York, New York, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Alexandria Real Estate Equities?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 53
Average round size 20M
Rounds per year 1.77
Peak activity year 2017
Lead investments 1
Follow on index 0.23
Exits 14
Group Appearance index 0.98

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

TFC Therapeutics

Biopharma
Biotechnology
Medical
17 Aug 2023 Nyack, New York, United States

Stablix

Biotechnology
Health Care
Medical
$63M03 Jun 2021 New York, New York, United States

Cradle Genomics

Biotechnology
$17M16 Jul 2019 San Diego, California, United States

Strand Therapeutics

Biotechnology
Therapeutics
$6M04 Jun 2019 Cambridge, Massachusetts, United States

KSQ Therapeutics

Biopharma
Biotechnology
Pharmaceutical
Therapeutics
$80M28 Sep 2018 Cambridge, Massachusetts, United States

KSQ Therapeutics

Biopharma
Biotechnology
Pharmaceutical
Therapeutics
$76M02 Oct 2017 Cambridge, Massachusetts, United States

Arbor Biotechnologies

Biopharma
Biotechnology
Life Science
$15M01 Jun 2017 Cambridge, Massachusetts, United States

Frequency Therapeutics

Biotechnology
Genetics
Medical
$32M11 Apr 2017 Woburn, Massachusetts, United States

GenePeeks

Biotechnology
Genetics
$16M24 Jan 2017 New York, New York, United States
Crunchbase icon

Content report

The following text will be sent to our editors: